177 related articles for article (PubMed ID: 2495179)
1. Combined effects of interferon alpha and interleukin 2 on the induction of a vascular leak syndrome in mice.
Puri RK; Rosenberg SA
Cancer Immunol Immunother; 1989; 28(4):267-74. PubMed ID: 2495179
[TBL] [Abstract][Full Text] [Related]
2. Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo.
Puri RK; Travis WD; Rosenberg SA
Cancer Res; 1989 Feb; 49(4):969-76. PubMed ID: 2783561
[TBL] [Abstract][Full Text] [Related]
3. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.
Rosenstein M; Ettinghausen SE; Rosenberg SA
J Immunol; 1986 Sep; 137(5):1735-42. PubMed ID: 3528289
[TBL] [Abstract][Full Text] [Related]
4. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice.
Ettinghausen SE; Puri RK; Rosenberg SA
J Natl Cancer Inst; 1988 Apr; 80(3):177-88. PubMed ID: 3258039
[TBL] [Abstract][Full Text] [Related]
5. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.
Puri RK; Leland P
Clin Exp Immunol; 1991 Aug; 85(2):317-25. PubMed ID: 1713814
[TBL] [Abstract][Full Text] [Related]
6. In vivo administration of interferon alpha and interleukin 2 induces proliferation of lymphoid cells in the organs of mice.
Puri RK; Travis WD; Rosenberg SA
Cancer Res; 1990 Sep; 50(17):5543-50. PubMed ID: 2386960
[TBL] [Abstract][Full Text] [Related]
7. Interferon gamma and interleukin 2 synergize to induce selective monokine expression in murine peritoneal macrophages.
Narumi S; Finke JH; Hamilton TA
J Biol Chem; 1990 Apr; 265(12):7036-41. PubMed ID: 2108965
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of interleukin 2-induced pulmonary vascular leak syndrome by low doses of oral methotrexate.
DeJoy SQ; Jeyaseelan R; Torley LW; Schow SR; Wick MM; Kerwar SS
Cancer Res; 1995 Nov; 55(21):4929-35. PubMed ID: 7585532
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1 alpha reduces the severity of the vascular leak syndrome produced by interleukin-2 and interleukin-2 plus interferon-alpha.
Fujita S; Puri R; Yu ZX; Travis W; Yamaguchi M; Ferrans VJ
Toxicol Pathol; 1994; 22(4):381-97. PubMed ID: 7817127
[TBL] [Abstract][Full Text] [Related]
10. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR
J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594
[TBL] [Abstract][Full Text] [Related]
11. Histamine improves survival and protects against interleukin-2-induced pulmonary vascular leak syndrome in mice.
Hornyak SC; Orentas DM; Karavodin LM; Gehlsen KR
Vascul Pharmacol; 2005 Mar; 42(4):187-93. PubMed ID: 15820445
[TBL] [Abstract][Full Text] [Related]
12. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
Agah R; Malloy B; Sherrod A; Bean P; Girgis E; Mazumder A
J Biol Response Mod; 1988 Apr; 7(2):140-51. PubMed ID: 3258905
[TBL] [Abstract][Full Text] [Related]
13. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
Gazit Z; Weiss DW; Shouval D; Yechezkeli M; Schirrmacher V; Notter M; Walter J; Kedar E
Cancer Immunol Immunother; 1992; 35(2):135-44. PubMed ID: 1596937
[TBL] [Abstract][Full Text] [Related]
14. Tumor-derived recognition factor (TDRF) induces production of TNF-alpha by murine macrophages, but requires synergy with IFN-gamma alone or in combination with IL-2 to induce nitric oxide synthase.
Jiang H; Stewart CA; Fast DJ; Leu RW
Int J Immunopharmacol; 1996; 18(8-9):479-90. PubMed ID: 9023587
[TBL] [Abstract][Full Text] [Related]
15. IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome.
Damle NK; Doyle LV
J Immunol; 1989 Apr; 142(8):2660-9. PubMed ID: 2522965
[TBL] [Abstract][Full Text] [Related]
16. Increasing infiltration and activation of CD8+ tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte/macrophage progenitor cells with low doses of interferon gamma plus tumor necrosis factor alpha.
Young MR; McCloskey G; Wright MA; Pak AS
Cancer Immunol Immunother; 1994 Jan; 38(1):9-15. PubMed ID: 8299123
[TBL] [Abstract][Full Text] [Related]
17. Human recombinant interleukin-2 provokes acute pulmonary vascular endothelial injury in rabbits.
Goldblum SE; Yoneda K; Cibull M; Pearson T; Hall C; Marshall ME
J Biol Response Mod; 1990 Apr; 9(2):127-39. PubMed ID: 2160520
[TBL] [Abstract][Full Text] [Related]
18. TNF-alpha and IFN-gamma reverse IL-4 inhibition of lymphokine-activated killer cell function.
Swisher SG; Economou JS; Holmes EC; Golub SH
Cell Immunol; 1990 Jul; 128(2):450-61. PubMed ID: 2113430
[TBL] [Abstract][Full Text] [Related]
19. Modulation of human endothelial cell permeability by combinations of the cytokines interleukin-1 alpha/beta, tumor necrosis factor-alpha and interferon-gamma.
Burke-Gaffney A; Keenan AK
Immunopharmacology; 1993; 25(1):1-9. PubMed ID: 8320078
[TBL] [Abstract][Full Text] [Related]
20. Vascular hyperpermeability induced by tumor necrosis factor and its augmentation by IL-1 and IFN-gamma is inhibited by selective depletion of neutrophils with a monoclonal antibody.
Abe Y; Sekiya S; Yamasita T; Sendo F
J Immunol; 1990 Nov; 145(9):2902-7. PubMed ID: 2120340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
